Chromenes: Potential new chemotherapeutic agents for cancer

Future Medicinal Chemistry

Volumn 5, Issue 14, 2013, Pages 1647-1660

  Patil, Shivaputra A ^a   Patil, Renukadevi ^a   Pfeffer, Lawrence M ^a   Miller, Duane D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 NITROPHENYL) 8,9,10,12 TETRAHYDRO 7H CHROMENO[4,3 B]QUINOLINE 6,8 DIONE; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 2H BENZO[H]CHROMEN 2 ONE; 4 AMINO 7,8,9,10 TETRAHYDRO 2H BENZO[H]CHROMEN 2 ONE; ANTINEOPLASTIC AGENT; CASPASE; CHROMENE DERIVATIVE; CHROMENOINDOLE; CHROMENOPYRIDINE; CHROMENOTRIAZOLOPYRIDINE; COLCHICINE; CROLIBULIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETOPOFOS; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; NEW DRUG; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PODOPHYLLOTOXIN; POLYCYCLIC CHROMENE; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PYRIDINE DERIVATIVE; TENIPOSIDE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD PRESSURE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HYPOTENSION; MICROTUBULE; NONHUMAN; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS;

EID: 84884537169     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.126     Document Type: Review

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
2. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 312, 1175-1178 (2006).
3. Croom KF, Perry CM. Imatinibmesylate: In the treatment of gastrointestinal stromal tumors. Drugs 63, 513-522 (2003).
4. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 1031-1037 (2001).
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
6. Dumontet C, Jordan MA. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790-803 (2010).
7. Downing KH, Nogales E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 10, 16-22 (1998).
8. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 1, 1-17 (2002).
9. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10(3), 194-204 (2010).
10. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061-1070 (1999).
11. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 10, 159-165 (2003).
12. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283 (2000).
13. Teodori E, Dei S, Martelli C et al. The functions and structure of ABC transporters: Implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7, 893-909 (2006).
14. Bellina F, Cauteruccio S, Monti S, Rossi R. Novel imidazole-based combretastatin A-4 analogues: Evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg. Med. Chem. Lett. 16, 5757- 5762 (2006).
15. Lippert JW 3rd. Vascular disrupting agents. Bioorg. Med. Chem. 15(2), 605-615 (2007).
16. Xu H, Lv M, Tian X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr. Med. Chem. 16(3), 327-349 (2009).
17. Nagar N, Jat RK, Saharan R, Verma S, Sharma D, Bansal K. Podophyllotoxin and their glycosidic derivatives. Pharmacophore 2(2), 124-134 (2011).
18. Lv M, Xu H. Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: An update (2008-2010). Mini Rev. Med. Chem. 11(10), 901-909 (2011).
19. Merzouki A, Buschmann MD, Jean M et al. Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells. Anticancer Res. 32(10), 4423-4432 (2012).
20. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34(10), 1514-1521 (1998).
21. Anthony SP, Von Hoff D, Whisnant JK, Tseng BY. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. J. Clin. Oncol. 25(18S), 14043 (2007).
22. Kemnitzer W, Drewe J, Jiang S et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group. J. Med. Chem. 47(25), 6299-6310 (2004).
23. Kemnitzer W, Kasibhatla S, Jiang S et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions. Bioorg. Med. Chem. Lett. 15(21), 4745-4751 (2005).
24. Kasibhatla S, Gourdeau H, Meerovitch K et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol. Cancer Ther. 3, 1365-1374 (2004).
25. Gourdeau H, Leblond L, Hamelin B et al. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol. Cancer Ther. 3, 1375-1383 (2004).
26. Patil SA, Wang J, Li XS et al. New substituted 4H-chromenes as anticancer agents. Bioorg. Med. Chem. Lett. 22(13), 4458-4461 (2012).
27. Shestopalov AM, Litvinov YM, Rodinovskaya LA, Malyshev OR, Semenova MN, Semenov VV. Polyalkoxy substituted 4H-chromenes: Synthesis by domino reaction and anticancer activity. ACS Comb. Sci. 14, 484-; 490 (2012).
28. Mahmoodi M, Aliabadi A, Emami S et al. Synthesis and in vitro cytotoxicity of poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes. Arch. Pharm. Chem. Life Sci. 343, 411-416, (2010).
29. Akbarzadeh T, Rafinejad A, Mollaghasem JM et al. 2-amino-3-cyano-4-(5- arylisoxazol-3-yl)-4H-chromenes: Synthesis and in vitro cytotoxic activity. Arch. Pharm. Chem. Life Sci. 345(5), 386-392 (2012).
30. Mansouri K, Khodarahmi R, Foroumadi A et al. Anti angiogenic/ proliferative behavior of a 4-aryl-4H-chromene on blood vessels endothelial cells: A possible evidence on dual anti-tumor activity. Med. Chem. Res. 20, 920-929 (2011).
31. Mahdavi M, Davoodi J, Zali MR, Foroumadi A. Concomitant activation of caspase-9 and down-regulation of IAP proteins as a mechanism of apoptotic death in HepG2, T47D and HCT-116 cells upon exposure to a derivative from 4-aryl-4H-chromenes family. Biomed. Pharmacother. 65, 175-182 (2011).
32. Aryapour H, Mahdavi M, Mohebbi SR,Zali MR, Foroumadi A. Anti-proliferative and apoptotic effects of the derivatives from 4-aryl-4H-chromene family on human leukemia K562 cells. Arch. Pharm. Res. 35(9), 1573-1582 (2012).
33. Khoshneviszadeh M, Edraki N, Miri R et al. QSAR Study of 4-aryl-4H-chromenes as a new series of apoptosis inducers using different chemometric tools. Chem. Biol. Drug Design 79(4), 442-458 (2012).
34. Su Y, Zhang X, Sinko PJ. Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: A promising new approach to the treatment of multidrug resistant cancer. Cancer Lett. 253, 115-123 (2007).
35. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 22, 8590-8607 (2003).
36. Wang J-L, Liu D, Zhang Z-J et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97(13), 7124-7129 (2000).
37. Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J. Med. Chem. 49(26), 7731-7739 (2006).
38. Das SG, Doshi JM, Tian D et al. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H- chromene-3-carboxylate (sha 14-11) and its analogues. J. Med. Chem. 52(19), 5937-5949 (2009).
39. Das SG, Srinivasan B, Hermanson DL et al. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy- 2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues. J. Med. Chem. 54(16), 5937-5948 (2011).
40. Aridoss G, Zhou B, Hermanson DL, Bleeker NP, Xing C. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment. J. Med. Chem. 55(11), 5566-5581 (2012).
41. Yu N, Aramini JM, Germann MW, Huang Z. Reactions of salicylaldehydes with alkyl cyanoacetates on the surface of solid catalysts: Syntheses of 4H-chromene derivatives. Tetrahedron Lett. 41, 6993-6996 (2000).
42. Doshi JM, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (HA 14-11), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol. Pharm. 4, 919-928 (2007).
43. Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C. sHA 14-11, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett. 259(2), 198-208 (2008).
44. Leahy JJ, Golding BT, Griffin RJ et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett. 14(24), 6083-6087 (2004).
45. Hardcastle IR, Cockcroft X, Curtin NJ et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J. Med. Chem. 48(24), 7829-7846 (2005).
46. Griffin RJ, Fontana G, Golding BT et al. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J. Med. Chem. 48(2), 569-585 (2005).
47. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev. 13(8), 916-934 (1999).
48. Izzard RA, Jackson SP, Smith GC. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 59(11), 2581-2586 (1999).
49. Aiello S, Wells G, Stone EL et al. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J. Med. Chem. 51(16), 5135-5139 (2008).
50. Wang JC. DNA topoisomerases. Annu. Rev. Biochem. 54, 665-697 (1985).
51. Thapa P, Lee E-S. 2,4-Diaryl-5H-chromeno [4,3-b]pyridines: Synthesis, topoisomerase I and II inhibitory activity, and cytotoxicity. Bull. Korean Chem. Soc. 33 (9), 3103-3106 (2012).
52. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr. Cancer Drug Targets 5(1), 57-68 (2005).
53. Hu C-Q, Hu Y-Z. Small molecule inhibitors of the p53-MDM2. Curr. Med. Chem. 15, 1720-1730 (2008).
54. Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin. Invest. Drugs 17, 1865-1882 (2008).
55. Allen JG, Bourbeau MP, Wohlhieter GE et al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J. Med. Chem. 52, 7044-7053 (2009).
56. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
57. Al-Said MS, El-Gazza MG, Ghorab MM. In vitro cytotoxic and radiosensitizing evaluation of novel 2-pyridone, isoquinoline, chromene and chromenopyridone derivatives. Eur. J. Chem. 3 (2), 228-234 (2012).
58. Guittat L, Alberti P, Rosu F et al. Interactions of cryptolepine and neocryptolepine with unusual DNA structures. Biochimie 85, 535-547 (2003).
59. Dassonneville L, Lansiaux A, Wattelet A et al. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: Relation to drug-induced apoptosis. Eur. J. Pharmacol. 409 (1) 9-18 (2000).
60. Bailly C, Laine W, Baldeyrou B et al. DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepine. Anticancer Drug Des. 15, 191-201 (2000).
61. Peng W, Switalska M, Wang L et al. Synthesis and in vitro antiproliferative activity of new 11-aminoalkylaminosubstituted chromeno[2,3-b]indoles. Eur. J. Med. Chem. 58, 441-451 (2012).
62. Reddy BV, Divya B, Swain M, Rao TP, Yadav JS, Vishnu Vardhan MV. A domino Knoevenagel hetero-Diels-Alder reaction for the synthesis of polycyclic chromene derivatives and evaluation of their cytotoxicity. Bioorg. Med. Chem. Lett. 22, 1995-1999 (2012).
63. Miri R, Motamedi R, Rezaei R, Firuzi O, Javidnia A, Shafiee A. Design, synthesis and evaluation of cytotoxicity of novel chromeno[4,3-b]quinoline derivatives. Arch. Pharm. Chem. Life Sci. 2, 111-118 (2011).
64. Kemnitzer W, Drewe J, Jiang S et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions. J. Med. Chem. 50(12), 2858-2864 (2007).
65. Kemnitzer W, Drewe J, Jiang S et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions. J. Med. Chem. 51(3), 417-423 (2008).
66. Kemnitzer W, Jiang S, Wang Y et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based HTS assay. Part 5: Modifications of the 2- and 3-positions. Bioorg. Med. Chem. Lett. 18(2), 603-607 (2008).
67. Kemnitzer W, Jiang S, Zhang H et al. Discovery of 4-aryl-2-oxo-2H- chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. Bioorg. Med. Chem. Lett. 18(20), 5571-5575 (2008).
68. Raju BC, Rao RN, Suman P et al. Synthesis, structure-activity relationship of novel substituted 4H-chromen-1,2,3,4-tetrahydropyrimidine-5- carboxylates as potential anti-mycobacterial and anticancer agents. Bioorg. Med. Chem. Lett. 21(10), 2855-2859 (2011).
69. Dong Y, Nakagawa-Goto K, Lai C-Y et al. Antitumor agents 278. 4-amino-2H-benzo[h]chromen-2-one (ABO) analogs as potent in vitro anti-cancer agents. Bioorg. Med. Chem. Lett. 20, 4085-4087 (2010).
70. Dong Y, Nakagawa-Goto K, Lai C-Y et al. Antitumor agents 281. Design, synthesis, and biological activity of substituted 4-amino-7,8,9,10-tetrahydro- 2H-benzo[h]chromen-2-one analogs (in situ) as potent in vitro anticancer agents. Bioorg. Med. Chem. Lett. 21, 546-549 (2011).
71. Dong Y, Nakagawa-Goto K, Lai C-Y et al. Antitumor Agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h] chromen-2-one and 4 amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility. J. Nat. Prod. 75, 370-377 (2012).
72. Wang X, Bastow KF, Sun CM et al. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J. Med. Chem. 47(23), 5816-5819 (2004).
73. Wang X, Nakagawa-Goto K, Bastow KF et al. Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J. Med. Chem. 49(18), 5631-5634 (2006).
74. Dong Y, Shi Q, Pai HC et al. Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. J. Med. Chem. 53(5), 2299-2308 (2010).